Search
Gadodiamide
go.drugbank.com/drugs/DB00225ApprovedInvestigationalGadodiamide is a linear, non-ionic gadolinium-based contrast agent (GBCA) that is used in magnetic resonance imaging (MRI) procedures to assist in the visualization of blood vessels. … [A263096] Approved by the FDA in 1993, gadodiamide is the first non-ionic GBCA to be used.
Categories: Compounds used in a research, industrial, or household settingProducts: OMNISCAN INJECTION 0.5MMOL/ML-10ML IN GLASS VIAL, OMNISCAN INJECTION 0.5MMOL/ML-20ML IN GLASS VIALArbutamine
go.drugbank.com/drugs/DB01102ApprovedArbutamine, administered through a closed-loop, computer-controlled drug-delivery system, is indicated to elicit acute cardiovascular responses, similar to those produced by exercise, in order to aid in … diagnosing the presence or absence of coronary artery disease in patients who cannot exercise adequately .
Categories: Compounds used in a research, industrial, or household settingCilgavimab
go.drugbank.com/drugs/DB16393ApprovedInvestigational[A243356, A243361] Cilgavimab (formerly AZD1061) is a recombinant monoclonal antibody produced in Chinese hamster ovary (CHO) cells derived from a neutralizing antibody isolated from a patient with a natural … Cilgavimab, in combination with [tixagevimab], was issued an FDA emergency use authorization (EUA) on December 9, 2021, for the pre-exposure prophylaxis of COVID-19 in individuals at increased risk for
Tixagevimab
go.drugbank.com/drugs/DB16394ApprovedInvestigational[A243356, A243361] Tixagevimab (formerly AZD8895) is a recombinant monoclonal antibody produced in Chinese hamster ovary (CHO) cells derived from a neutralizing antibody isolated from a patient with a … Tixagevimab, in combination with [cilgavimab], was issued an FDA emergency use authorization (EUA) on December 9, 2021, for the pre-exposure prophylaxis of COVID-19 in individuals at increased risk for
Streptococcus pneumoniae type 22f capsular polysaccharide antigen
go.drugbank.com/drugs/DB10339ApprovedInvestigationalIt is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia. … Streptococcus pneumoniae type 22f capsular polysaccharide antigen is a vaccine that contains highly purified capsular polysaccharides from the invasive pneumococcal type 22f of *Streptococcus pneumoniae
Mixtures: PNEUMOVAX 23 Injektionslösung in einer Fertigspritze, PNEUMOVAX 23 Injektionslösung in einer DurchstechflascheBamlanivimab
go.drugbank.com/drugs/DB15718ApprovedInvestigationalBamlanivimab (LY-CoV555, also known as LY3819253), is a synthetic monoclonal antibody (mAb) derived from one of the first blood samples in the United States from a patient who recovered from COVID-19. … [A224039, L15311, L15316] Bamlanivimab is a neutralizing IgG1κ mAb directed against the SARS-CoV-2 spike (S) protein, which is described to block viral entry into human cells.
Gemeprost
go.drugbank.com/drugs/DB08964ApprovedWithdrawnGemeprost is a prostaglandin E1 (PGE1) analog and antiprogestogen used for preoperative dilation of the cervix before surgical abortion. … It is not FDA-approved but available in Japan marketed as Preglandin.
Synonyms: 16,16-Dimethyl-trans-delta(sup 2)-prostaglandin E1 methyl esterCategories: Prostaglandins E, Prostaglandins E, SyntheticClonixin
go.drugbank.com/drugs/DB09218InvestigationalClonixin is a non-steroidal anti-inflammatory drug.
Mixtures: PRESTOFLAM LD, PRESTOFLAM LDPoliovirus type 2 antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB10796ApprovedInvestigationalPoliovirus type 2 antigen is a suspension of poliovirus Type 2 (MEF-1) used in the active immunization of infants (as young as 6 weeks of age), children, and adults for the prevention of poliomyelitis … The vaccine contains purified and inactivated poliovirus type 2 that were grown from a continuous line of monkey kidney cells.
Mixtures: VeroPol Injektionslösung in einer Fertigspritze, -POLIO SUSPENSION FOR INJECTION IN PRE-FILLED SYRINGEAmivantamab
go.drugbank.com/drugs/DB16695ApprovedInvestigationalFDA approved the subcutaneous formulation, RYBREVANT FASPRO™, across all existing and expanded indications of amivantamab, including its use as a first-line, chemotherapy-free combination regimen with … [A235133] Amivantamab was granted FDA approval on 21 May 2021,[L34193] followed by the approval by the EMA on 9 December 2021 [L41474] and Health Canada on 30 March 2022.